Gland Pharma gets EIR for Pashamylaram Facility

24 Nov 2023 Evaluate

Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection at Pashamylaram Facility, Hyderabad. The Pre-Market Inspection covering USFDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) by USFDA conducted at the Company’s Pashamylaram Facility at Hyderabad between August 23, 2023 and August 26, 2023.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1639.70 -13.65 (-0.83%)
29-Dec-2025 11:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1723.40
Dr. Reddys Lab 1260.30
Cipla 1498.50
Zydus Lifesciences 904.60
Lupin 2085.80
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×